ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1964

Performance of Artificial Intelligence-Based Salivary Gland Ultrasound in Sjögren Syndrome
Abstract Number: 0126

Performance of the 2023 and 2006 APS Classification Criteria in Pediatric Patients Diagnosed with APS: A Multisite Cohort Study
Abstract Number: 0468

Performance of the expanded cardiovascular risk prediction score for rheumatoid arthritis (ERS-RA) in a nationwide multicenter Chinese cohort
Abstract Number: 2569

Performance of the PREVENT Heart Failure General Population Risk Score in Patients with Rheumatoid Arthritis
Abstract Number: 1950

Pericoronary fat enhancement in rheumatoid arthritis differs from controls and associates with coronary atherosclerosis independently of epicardial fat volume
Abstract Number: 1169

Periodontitis in neutropenic DADA2 patients
Abstract Number: 0350

Perioperative Evaluation of Blood Tests Including Bone Turnover Markers in Patients Undergoing Surgery for Proximal Femur Fractures
Abstract Number: 2307

Peripheral Manifestations In Axial And Peripheral Spondyloarthritis: A Systematic Literature Review On Their Assessment In Clinical Trials
Abstract Number: 0580

Persistence and Disease Activity Control among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy
Abstract Number: 0577

Persistence and Effectiveness Across PsA Patient Subgroups with Guselkumab and IL-17 Inhibitors: 6-Month Results of the PsABIOnd Observational Study
Abstract Number: 1446

Persistence of Second-line Treatment in Anti-TNF-experienced Axial Spondyloarthritis Patients: Comparing Cycling Anti–TNF vs Switching to a Different Mechanism of Action
Abstract Number: 0816

Persistent Pain Despite Inflammatory Control in RA: A Pooled Analysis of 7 RCTs
Abstract Number: 2327

Persistent Pain in PsA: A Distinct Phenotype of Depression, Fatigue, And Catastrophizing
Abstract Number: 1262

Perspectives of Lupus Patients on Quality of Life Measures: A Qualitative Study
Abstract Number: 1506

Perspectives on Clinical Trial Participation for Novel Advanced Therapies: A Focus Group Study in Systemic Lupus Erythematosus (SLE)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].